Gadbail Amol R, Chaudhary Minal S, Sarode Sachin C, Gondivkar Shailesh M, Belekar Lalita, Mankar-Gadbail Mugdha P, Dande Ravi, Tekade Satyajit A, Yuwanati Monal B, Patil Shankargouda
Department of Dentistry, Indira Gandhi Government Medical College and Hospital, Nagpur, India.
Department of Oral Pathology and Microbiology, Sharad Pawar Dental College and Hospital, Datta Meghe Institute of Medical Sciences, Sawangi, India.
J Investig Clin Dent. 2019 Nov;10(4):e12443. doi: 10.1111/jicd.12443. Epub 2019 Jul 19.
The aim of this study was to investigate the expression of Ki67, CD105 and α-smooth muscle actin (α-SMA) expression in oral submucous fibrosis (OSF) and oral squamous cell carcinoma in the background of OSF (OSCC-SMF).
The study was carried out on paraffin-embedded tissues of 30 normal oral mucosa (NOM), 50 OSF cases and 105 OSCC-SMF. The immunohistochemistry was carried out to evaluate the expression of Ki67, CD105 and α-SMA antigen.
Ki67 labelling index (LI), CD105 and α-SMA expression showed increasing trend from NOM, low-risk epithelial dysplasia (LRED), high-risk epithelial dysplasia (HRED), well-differentiated squamous cell carcinoma (WDSCC), moderately differentiated squamous cell carcinoma to poorly differentiated squamous cell carcinoma. However, there was no significant difference of α-SMA expression between HRED and WDSCC. In OSCC-SMF, Ki67 LI, CD105 and α-SMA were significantly higher in advanced clinical TNM stage, metastasis and less than 3 years patient survival as compared with early clinical TNM stage, non-metastasis and 3 years or more patient survival.
Ki67 LI, α-SMA and CD105 expression alone or together correspond with the disease progression model of SMF. Hence, expression of these markers can be used as a predictive marker of clinical outcome of OSCC-SMF.
本研究旨在调查口腔黏膜下纤维化（OSF）以及OSF背景下的口腔鳞状细胞癌（OSCC-SMF）中Ki67、CD105和α平滑肌肌动蛋白（α-SMA）的表达情况。
对30例正常口腔黏膜（NOM）、50例OSF病例和105例OSCC-SMF的石蜡包埋组织进行研究。采用免疫组织化学方法评估Ki67、CD105和α-SMA抗原的表达。
Ki67标记指数（LI）、CD105和α-SMA的表达从NOM、低风险上皮异常增生（LRED）、高风险上皮异常增生（HRED）、高分化鳞状细胞癌（WDSCC）、中分化鳞状细胞癌到低分化鳞状细胞癌呈上升趋势。然而，HRED和WDSCC之间α-SMA的表达无显著差异。在OSCC-SMF中，与临床TNM早期、无转移和患者生存3年或更长时间相比，Ki67 LI、CD105和α-SMA在临床TNM晚期、有转移和患者生存不到3年时显著更高。
单独或联合检测Ki67 LI、α-SMA和CD105的表达与SMF的疾病进展模式相符。因此，这些标志物的表达可作为OSCC-SMF临床结局的预测指标。
